Patient-reported outcomes in a randomized trial of everolimus with metastatic renal cell carcinoma patients

被引：0
|
作者：
Beaumont, J.
Cella, D.
Hutson, T.
Bracarda, S.
Gruenwald, V.
Thompson, J.
Ravaud, A.
Urbanowitz, G.
Hollaender, N.
Motzer, R.
机构：
[1] Ctr Outcomes Res & Educ, Evanston, IL USA
[2] Ctr Outcomes Res & Educ, Chicago, IL USA
[3] US Oncol, Baylor Sammons Canc Ctr, Dallas, TX USA
[4] Azienda Osped, Perugia, Italy
[5] Hannover Med Sch, D-3000 Hannover, Germany
[6] Canc Care Alliance, Seattle, WA USA
[7] CHU Bordeaux, Hop St Andre, Bordeaux, France
[8] Novartis, Oncol, Florham Pk, NJ USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17516
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A Delphi Study of Core Patient-Reported Outcomes for Advanced Renal Cell Carcinoma and Advanced Hepatocellular Carcinoma
    de la Serna, Celia Diez de los Rios
    Drury, Amanda
    Oldenmenger, Wendy H.
    Kelly, Daniel
    Kotronoulas, Grigorios
    SEMINARS IN ONCOLOGY NURSING, 2023, 39 (04)
  • [22] Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment
    Nolla, Kyle
    Benjamin, David J.
    Cella, David
    NATURE REVIEWS UROLOGY, 2023, 20 (07) : 420 - 433
  • [23] ASPEN: A randomized phase II trial of everolimus versus sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    Armstrong, Andrew J.
    Halabi, Susan
    Eisen, Tim
    Stadler, Walter Michael
    Jones, Robert R.
    Vaishampayan, Ultra N.
    Garcia, Jorge A.
    Hawkins, Robert E.
    Kollmannsberger, Christian K.
    Lusk, Christine
    Broderick, Samuel
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment
    Kyle Nolla
    David J. Benjamin
    David Cella
    Nature Reviews Urology, 2023, 20 : 420 - 433
  • [25] The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial
    Lærke K. Tolstrup
    Lars Bastholt
    Karin B. Dieperink
    Sören Möller
    Ann-Dorthe Zwisler
    Helle Pappot
    Journal of Patient-Reported Outcomes, 4
  • [26] The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial
    Tolstrup, Laerke K.
    Bastholt, Lars
    Dieperink, Karin B.
    Moeller, Soeren
    Zwisler, Ann-Dorthe
    Pappot, Helle
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2020, 4 (01)
  • [27] Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
    Cella, D.
    Escudier, B.
    Rini, B. I.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Molina, A. M.
    Feldman, D. R.
    Ginsberg, M. S.
    Fischer, P.
    Trinos, M. J.
    Patil, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [29] Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib
    Iacovelli, Roberto
    Carteni, Giacomo
    Milella, Michele
    Berardi, Rossana
    Di Lorenzo, Giuseppe
    Verzoni, Elena
    Rizzo, Mimma
    Santoni, Matteo
    Procopio, Giuseppe
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2014, 8 (3-4): : E121 - E125
  • [30] Patient-reported outcomes in patients with metastatic renal cell carcinoma treated with systemic first-line therapy: Interim results of the PROKidney cohort study
    Kirste, T.
    Werner, T.
    Scheffler, M.
    Hamm, N.
    Eckert, R.
    Pelz, H.
    Fichter, C.
    Mueller, L.
    Sahlmann, J.
    Potthoff, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 204 - 204
12345